As the prevalence of obesity, type 2 diabetes, and the opioid crisis in the United States continues to rise, so does chronic liver disease. From hepatitis C and hepatitis B to non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), liver disease affects a significant portion of the U.S. population. Hepatitis C virus (HCV) is a leading cause of cirrhosis, liver cancer, and mortality worldwide. Injection drug use, arising in conjunction with the opioid crisis, has contributed significantly to the increase in HCV infections. Chronic hepatitis B virus (HBV) remains a global epidemic, resulting in significantly increased morbidity and mortality. Furthermore, the rising number of obese and diabetic patients has resulted in the increased prevalence of NAFLD, which may progress to NASH in a large number of patients. To help clinicians and patients navigate the changing landscape of liver disease, we designed the Liver Disease Hub to provide resources and guidelines for screening, testing, and treatment of liver disease.

Our activities offer many credit types, including CME, AAFP Prescribed Credit, CNE, CPE, ABIM MOC, and ABP MOC. Each activity has been designed to meet the requirements for CME for MIPS. See each activity’s information page for the exact credit type and amount of credit offered.

Saturday Morning Coffee with Experts in NASH: What Is The Update?

Participate Now

In this CME Outfitters webcast, a renowned panel of experts will highlight the underlying mechanisms of NASH via innovative augmented reality (AR) animations and present real-world case scenarios to share clinical insights on how to choose appropriate non-invasive diagnostic modalities, as well as translate latest data on emerging targeted therapies and their implications for clinical practice.

Streamlining the Journey to a Cure: Optimizing the Hepatitis C Virus Care Cascade

Participate Now

Recent studies have shown persistent gaps in the HCV care continuum, with underdiagnosis and undertreatment being the major barriers toward achieving the goal of eliminating HCV. With primary care clinicians and community health workers representing an important front-line resource for early screening and treatment for HCV infection, it is imperative to educate primary care providers (PCPs) and community health workers to expand the HCV workforce and linkage-to-care opportunities.  This CME Outfitters on-demand webcast features expert faculty hosting an interactive discussion on implementing HCV screening, developing new methods of coordinated care, and addressing barriers to treatment access.

 

 

At-Risk Patients Hidden in Plain Sight: Real-World Strategies for Screening and Treating Hepatitis B Virus

Participate Now

In this CME Outfitters virtual symposium, expert faculty utilized augmented reality to add visualization to their discussion of how to implement routine screening protocols for HBV in primary care settings, how to optimize the efficacy and safety profiles of current

A Deeper Dive into NASH Diagnosis and Treatment: An Augmented Reality Experience

Participate Now

With the majority of high-risk patients first seen in the primary care setting, it is imperative that internists and primary care physicians (PCPs) identify patients at risk for NASH. Although liver biopsy was previously the best test for identifying the critical endpoints of NASH, several noninvasive, yet effective, tests have been developed recently that have the potential to be implemented in primary care settings. In this CME Outfitters webcast, expert faculty utilized Augmented Reality (AR) to visually dive into NASH, with particular focus on risk stratification, diagnosis, and emerging targeted therapies.

A Grassroots Approach to Weed Out HIV and HCV in Special OUD Populations

Participate Now

In this CME Outfitters on-demand webcast, expert faculty discuss strategies for HIV and HCV testing in special OUD populations, applying evidence-based treatment approaches, as well as prevention strategies, including PrEP, for patients with OUD at high risk for HIV infection.

What the Future Holds for NASH: An Augmented Reality Look into Disease Stating and Targeted Therapies

Participate Now

Given the rising prevalence of non-alcoholic fatty liver disease (NAFLD) and the societal and economic burden of its aggressive subtype, non-alcoholic steatohepatitis (NASH), it is important that hepatologists and gastroenterologists are equipped with the latest tools to diagnose NASH. This CME Outfitters OnDemand features expert faculty integrating augmented reality (AR) to discuss pathways, therapeutic targets, and disease progression providing the learners with the best visual experience to enable them to integrate the latest tools for diagnosis and management of patients with NASH.

Overcoming Challenges in HIV and HCV Testing and Linkage to Care

Participate NowThe first part of this CME Outfitters BriefCase, a case-based faculty interview, examines a real-world case highlighting strategies for testing at-risk patients for HIV and HCV, including OUD populations. Further, faculty discuss how to interpret lab results and the appropriate steps to take for this patient population.

Comprehensive Approaches for HIV Prevention in High-Risk Patients with OUD

Participate NowThe second part of this CME Outfitters BriefCase, a case-based faculty interview, aims to educate clinicians on PrEP for HIV prevention, including what patients are - or are not - candidates for PrEP, as well as the necessary steps to take before initiating PrEP.

Management of a Patient with HIV-HCV Coinfection and Substance Use Disorder

Participate NowThe final installment of this three-part CME Outfitters BriefCase, a case-based faculty interview, features expert faculty discussing implementation of team-based approaches for the management of patients with HIV-HCV coinfection and substance use disorder in order to improve care for these patients.

A Grassroots Approach to Weed Out HIV and HCV in Special OUD Populations

Participate NowIn this CMEO Podcast, expert faculty discuss strategies for HIV and HCV testing in special OUD populations, applying evidence-based treatment approaches, as well as prevention strategies, including PrEP, for patients with OUD at high risk for HIV infection.

NASH

NASH Pathophysiology

In this video, Dr. Mazen Noureddin uses an augmented reality animation of the human liver to describe how nonalcoholic steatohepatitis (NASH) emerges.

Molecular Targets for Emerging Therapies for NASH

In this video, Dr. Mazen Noureddin uses an augmented reality animation of the human liver to review molecules that play key roles in NASH pathophysiology and have thus been identified as targets for the development of pharmacotherapies for NASH.